Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
P/E(ttm) 21.96
IYH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IYH: 21.96 )
Ranked among companies with meaningful P/E(ttm) only.
IYH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.27
Current: 21.96
0
24.27
PE(NRI) 21.96
IYH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IYH: 21.96 )
Ranked among companies with meaningful PE(NRI) only.
IYH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.27
Current: 21.96
0
24.27
P/B 3.47
IYH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IYH: 3.47 )
Ranked among companies with meaningful P/B only.
IYH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.95
Current: 3.47
0
3.95

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.03
IYH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IYH: 2.03 )
Ranked among companies with meaningful Dividend Yield only.
IYH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.3
Current: 2.03
0
2.3
Yield on cost (5-Year) 2.03
IYH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IYH: 2.03 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IYH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.3
Current: 2.03
0
2.3

More Statistics

Short Percentage of Float0.00%
52-Week Range $136.71 - 157.13
Shares Outstanding (Mil)11,600,000.00
» More Articles for IYH

Headlines

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Fairholme's Bruce Berkowitz Responds to Court Ruling Against Hedge Fund Suits of Fannie Mae Feb 22 2017 
Will Procter & Gamble Raise Dividend in 2017? Feb 22 2017 
The Coffee Can Portfolio Feb 22 2017 
Gernstein Fisher: What’s a $20 Trillion Debt Among Friends? Feb 22 2017 
Abbott Laboratories Declares Quarterly Dividend Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on OCI Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on Level 3 Communications Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on Scripps Networks Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on Wynn Resorts Feb 22 2017 

More From Other Websites
How to Play Pfizer's Fourth-Quarter Results With ETFs Feb 01 2017
Why GE’s Healthcare Revenues Rose in 4Q16 Jan 27 2017
Analyzing Bristol-Myers Squibb’s Other Segments in 4Q16 Jan 25 2017
How Should Investors Play Healthcare? Jan 24 2017
3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter Jan 24 2017
Why health-care stocks aren’t moving after President Trump’s Obamacare executive order Jan 24 2017
U.S. fund managers betting Trump fails to rewrite Obamacare Jan 24 2017
What’s Expected from Bristol-Myers Squibb’s 4Q16 Earnings? Jan 23 2017
Can Q4 Earnings Revitalize Healthcare ETFs? Jan 23 2017
Will Johnson & Johnson’s Profitability Improve in 4Q16? Jan 23 2017
A Look Into The Economic And Human Cost Of A Partial Obamacare Repeal Jan 12 2017
Gilead Sciences’ Liver Disease Drugs Portfolio Jan 02 2017
What Factors Are Contributing to Gilead Sciences’ Growth? Dec 30 2016
The Competitive Landscape for Enbrel Dec 29 2016
What’s Behind Amgen’s Discounted Valuation? Dec 28 2016
2 Beaten-Down Funds To Buy For 9.4% Dividends, And 3 To Avoid Dec 24 2016
Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug Dec 21 2016
Pfizer Has Strong Track Record since 2010 Dec 15 2016
How Much Could Pfizer Grow beyond 2016? Dec 14 2016
Lyrica to Lose Patent Protection in the US in 2018 Dec 14 2016
Listing the Reasons behind Pfizer’s Discounted Price-to-Earnings Dec 09 2016
Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares Dec 07 2016
The Fuel for Today’s Reflationary Fire: What You Need to Know Dec 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK